Skip to main content

Advertisement

SpringerLink
Log in

The influence of hiv coinfection on the natural history of hcv infection

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

In the United States, it is estimated that more than 4 million people are infected with the hepatitis C virus (HCV) and over 1.25 million are infected with HIV. With common routes of transmission, approximately 30% of HIV-infected individuals are coinfected with HCV. Deaths due to opportunistic infections from HIV declined with the advent of highly active antiretroviral therapy, whereas manifestations of end-stage liver disease have become more apparent with the increased longevity. Current efforts are directed toward understanding whether HIV/HCV coinfection affects the natural history of each virus. Early outcomes in treating coinfected patients for their HCV were below expectations, whereas recent treatment trials with highly selected patients and newer therapeutic agents have shown greater success. The aim of this paper is to review the epidemiology, natural history, and treatment outcomes, as well as unique challenges in the management of HIV/HCVcoinfected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Prince AM, Brotman B, Grady GF, et al.: Long-incubation posttransfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 1974, 2:241–246.

    Article  PubMed  CAS  Google Scholar 

  2. Alter MJ: The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997, 1:559–568, vi–vii.

    Article  PubMed  CAS  Google Scholar 

  3. Schiff ES, Maddrey W, Sorrell MF, eds: Schiff’s Diseases of the Liver, edn 9 (2-volume set). Philadelphia: Lippincott Williams & Williams; 2002.

    Google Scholar 

  4. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al.: HIV coinfection shortens the survival of patients with hepatitis C virusrelated decompensated cirrhosis. Hepatology 2005, 41:779–789.

    Article  PubMed  Google Scholar 

  5. Wong W, Terrault N: Update on chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:507–520.

    Article  PubMed  CAS  Google Scholar 

  6. Lichterfeld M, Schmeisser N, Qurishi N, et al.: Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005, 50:221–228.

    Article  PubMed  Google Scholar 

  7. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.

    Article  PubMed  CAS  Google Scholar 

  8. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831–837.

    Article  PubMed  Google Scholar 

  9. Verucchi G, Calza L, Manfredi R, Chiodo F: Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004, 32:33–46.

    Article  PubMed  CAS  Google Scholar 

  10. Yoo TW, Donfield S, Lail A, et al.: Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005, 191:4–10. Found increased risk of progression to AIDS in HCV-coinfected patients.

    Article  PubMed  Google Scholar 

  11. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800–1805.

    Article  PubMed  CAS  Google Scholar 

  12. Antonucci G, Girardi E, Cozzi-Lepri A, et al.: Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005, 40:e101-e109.

    Article  PubMed  Google Scholar 

  13. Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288:199–206. United States-based study found that HCV/HIV coinfection did not increase risk of progression to AIDS.

    Article  PubMed  Google Scholar 

  14. French AL, Benning L, Anastos K, et al.: Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004, 39:402–410.

    Article  PubMed  CAS  Google Scholar 

  15. Martinez E, Blanco JL, Arnaiz JA, et al.: Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15:1261–1268.

    Article  PubMed  CAS  Google Scholar 

  16. Mocroft A, Phillips AN, Soriano V, et al.: Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:527–536.

    Article  PubMed  CAS  Google Scholar 

  17. Dieterich D, Robinson P, Love J, Stern J: Drug-induced liver injury associated with the use of non-nucleoside reverse transcriptase inhibitors. Clin Infect Dis 2004, 38:S80-S90.

    Article  PubMed  CAS  Google Scholar 

  18. Sulkowski MS, Mehta SH, Torbenson M, et al.: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19:585–592.

    Article  PubMed  Google Scholar 

  19. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.

    Article  PubMed  CAS  Google Scholar 

  20. Benhamou Y, DiMartino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283–287.

    Article  PubMed  CAS  Google Scholar 

  21. Nunez M, Rios P, Martin-Carbonero L, et al.: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 30:65–68.

    Article  PubMed  Google Scholar 

  22. Sterling R, Contos M, Sanyal A, et al.: The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 2003, 32:30–37.

    PubMed  CAS  Google Scholar 

  23. Rockstroh J, Konopnicki D, Soriano V, et al.: Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART [abstract 799]. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  24. Mohsen AH, Easterbrook PJ, Taylor C, et al.: Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003, 52:1035–1040.

    Article  PubMed  CAS  Google Scholar 

  25. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054–1058.

    Article  PubMed  CAS  Google Scholar 

  26. Soto B, Sanchez-Quijano A, Rodrigo L, et al.: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1–5.

    Article  PubMed  CAS  Google Scholar 

  27. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562–569.

    Article  PubMed  CAS  Google Scholar 

  28. Monga HK, Rodriguez-Barradas MC, Breaux K, et al.: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 33:240–247.

    Article  PubMed  CAS  Google Scholar 

  29. Di Martino V, Ezenfis J, Tainturier M, et al.: Impact of HIV coinfection on the long-term outcome of HCV cirrhosis. Paper presented at the Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA; February 24–28, 2002.

  30. Brau N, Rodriguez-Torres M, Salvatore M, et al.: Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV/HCVcoinfection and makes it the same as in HCV-monoinfection. The Puerto Rico-New York Hepatitis C Study Group. J Hepatol 2004, 40:33A.

    Article  Google Scholar 

  31. Oliver D, Barber E, Chatfield E, et al.: Impact of HAART on survival of patients with HCV/HIV coinfection [abstract 1615]. Hepatology 2002, 36:567A.

    Google Scholar 

  32. De Luca A, Bugarini R, Lepri AC, et al.: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002, 162:2125–2132.

    Article  PubMed  Google Scholar 

  33. Martin-Carbonero L, Benhamou Y, Puoti M, et al.: Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004, 38:128–133.

    Article  PubMed  Google Scholar 

  34. Mehta S, Thomas D, Torbenson M, et al.: The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2004, 41:123–131.

    Article  Google Scholar 

  35. Kramer JR, Giordano TP, Souchek J, et al.: The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005, 100:56–63.

    Article  PubMed  Google Scholar 

  36. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al.: HIV coinfection shortens the survival of patients with hepatitis C virusrelated decompensated cirrhosis. Hepatology 2005, 41:779–789.

    Article  PubMed  Google Scholar 

  37. Lichterfeld M, Haas S, Fischer HP, et al.: Liver histopathology in human immunodeficiency virus-hepatitis C virus coinfected patients with fatal liver disease. J Gastroenterol Hepatol 2005, 20:739–745.

    Article  PubMed  Google Scholar 

  38. Zimmerman HJ, ed: The spectrum of hepatotoxicity. In Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia: Lippincott, Williams & Wilkins; 1999:3–10.

    Google Scholar 

  39. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708–1713.

    Article  PubMed  CAS  Google Scholar 

  40. Rutschmann OT, Negro F, Hirschel B, et al.: Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998, 177:783–785.

    Article  PubMed  CAS  Google Scholar 

  41. Garcia-Samaniego J, Bravo R, Castilla J, et al.: Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998, 28:526–527.

    Article  PubMed  CAS  Google Scholar 

  42. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848.

    Article  PubMed  CAS  Google Scholar 

  43. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459.

    Article  PubMed  CAS  Google Scholar 

  44. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438–450. Largest study for HCV therapy in coinfected patients using combination therapy of pegylated interferon and ribavirin.

    Article  PubMed  CAS  Google Scholar 

  45. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  46. Vogel M, Bieniek B, Jessen H, et al.: Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005, 12:207–211.

    Article  PubMed  CAS  Google Scholar 

  47. Mangia A, Santoro R, Minerva N, et al.: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609–2617.

    Article  PubMed  CAS  Google Scholar 

  48. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265–2271.

    Article  PubMed  CAS  Google Scholar 

  49. Sterling RK, Wilson MS, Sanyal AJ, et al.: Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol 2004, 2:432–439.

    Article  PubMed  CAS  Google Scholar 

  50. Fleming CA, Craven DE, Thornton D, et al.: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003, 36:97–100.

    Article  PubMed  Google Scholar 

  51. Ilyas J, Oliver D, Barber E, et al.: Factors that influence treatment of HIV/HCV co-infected patients. Gastroenterology 2005, 128:720–721A.

    Google Scholar 

  52. Fiellin DA, O’Connor PG, Chawarski M, Schottenfeld RS: Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict 2004, 13(suppl 1):S67-S78.

    Article  PubMed  Google Scholar 

  53. Piasecki BA, Lewis JD, Reddy KR, et al.: Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004, 40:892–899.

    PubMed  Google Scholar 

  54. Fleming CA, Tumilty S, Murray JE, Nunes D: Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005, 40(suppl 5):S349-S354.

    Article  PubMed  Google Scholar 

  55. Restrepo A, Johnson TC, Widjaja D, et al.: The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005, 12:86–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, School of Medicine, University of California, 200 West Arbor Drive MC 8707, 92103-8707, San Diego, CA, USA

    Tarek I. Hassanein MD

Authors
  1. Arun Swaminath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deanna L. Oliver
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew C. McNeil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tarek I. Hassanein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swaminath, A., Oliver, D.L., McNeil, A.C. et al. The influence of hiv coinfection on the natural history of hcv infection. Curr hepatitis rep 4, 131–137 (2005). https://doi.org/10.1007/s11901-005-0028-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-005-0028-y

Keywords

Search

Navigation